Category Archives: Stem Cells

CBS Pittsburgh (con't)

Affordable Care Act Updates: CBSPittsburgh.com/ACA

Health News & Information: CBSPittsburgh.com/Health

PITTSBURGH (NewsRadio 1020 KDKA) Stem cells have been used to treat cancer patients, multiple sclerosis and other conditions. Now, a local practice, Rehabilitation and Pain Specialists, is bringing to the Pittsburgh area a non-surgical adult stem cell procedure to treat pain in patients.

Dr. Marc Adelsheimer, the CEO Of Rehabilitation and Pain Specialists, joined KDKA Radios Larry Richert and John Shumway to talk about the procedure coming to western PA called Regenexx.

Stem cells have been a controversial topic for years and have caused debate among government officials and various groups. The question people want to know is, where do the stem cells come from? Dr. Adelsheimer wants people to know, the cells that we use are your own stem cells.

He adds they are not using embryonic stem cells but ones that are already present in the patients body.

Theyre in high concentration within [your] bone marrow, we isolate them from the bone marrow and we inject them into the damaged tissue, adds Dr. Adelsheimer.

The procedure could possibly reverse some of the arthritic processes, within ones body, the doctor said. Since the procedure is non-surgical it could help people avoid, a major surgery.

Dr. Adelsheimer says the reason stem cells can help possibly fix conditions like joint injuries, osteoarthritis and non-healing fractures is because stem cells are the cells that heal the body and can turn it any other cell. says Dr. Adelsheimer.

Read the original:
New Stem Cell Procedure Gives Hope To Pain Sufferers

Stem Cells Anti-Aging Study - Caleb #39;s testimonial after 6 ESC injections
http://a1stemcells.com/anti-aging-2 testimony of Caleb, 36yo, recorded during his 7th injection. It changed Caleb #39;s life. Stem cell rejuvenation program in M...

By: Cure4Cancers

Read more:
Stem Cells Anti-Aging Study - Caleb's testimonial after 6 ESC injections - Video

San Jose, California (PRWEB) January 20, 2014

Follow us on LinkedIn Cancer Stem Cells (CSCs) are the cells within a tumor that possess the capability of self-renewal, driving tumorigenesis. Fuelled by the need for more effective treatment options and growing focus of the medical community to develop drugs and therapies that target tumor roots, research in the field of Cancer Stem Cells (CSCs) is attracting increased investments. Stem cells also known as progenitor cells, represent cells that are capable of regenerating malignant tumor cells and thus are responsible for the spread of cancer. As a key cause for tumor recurrence, metastasis, and resistance, cancer stem cells are therefore an important theme for R&D, especially as a drug target. The coming years are forecast to witness the development of novel drugs that target cancer stem cells (CSCs). Research efforts concerning CSCs would be focused on development of in vitro and in vivo methods for identification of CSCs and related biomarkers that would help understand the principles of tumour development and metastasis. Growing demand for effective and accurate cancer detection methodologies against the backdrop of rising cancer incidence is forecast to boost market prospects in the coming years.

The trend report titled Cancer Stem Cells announced by Global Industry Analysts Inc., is a focused research paper which provides cursory insights into the product, its applications, future prospects, and corporate initiatives of key companies worldwide. Also covered are companies such as Boston Biomedical Inc., Macrogenics, and Verastem, Inc.

For more details about this trend report, please visit http://www.strategyr.com/TrendReport.asp?code=141066

About Global Industry Analysts, Inc. Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.

Global Industry Analysts, Inc. Telephone: 408-528-9966 Fax: 408-528-9977 Email: press(at)StrategyR(dot)com Web Site: http://www.StrategyR.com/

###

Go here to see the original:
Rising Prevalence of Cancer Drives the Market for Cancer Stem Cells, According to a New Trend Report Published by ...

Umbilical cord stem cell banking can be expensive and controversial, but Jamie and Ben Page decided to bank their daughter, Harlow's stem cells just in case.

"We had heard about cord blood banking and talked about it a lot and thought let's just go for it and have it just as a backup," Jamie Page said.

They did need it. Harlow had cancer in her uterus.

"On the ultrasound they immediately saw that there was a mass in her abdomen about the size of a grapefruit," Page said.

After a year of chemo, the tumor was gone. Doctors wanted to keep it that way.

"So, when the doctors found out we actually had her own stem cells, they were very excited," Page said.

Oncologist Elaine Morgan says those stem cells helped Harlow.

"I think that her umbilical cord cells were used as a boost to her own cells when we harvested her to have adequate cells for reconstitution," Dr. Morgan said.

Dr. Morgan does not advocate private cord stem cell banking at birth to be saved for a healthy baby's later use, because it's not clinically useful and it's expensive.

The Pages paid almost $2,000 for the initial banking fee, plus an extra $125 per year.

Read more here:
The Practicing Parent: Pros & cons of stem cell banking

Lady's own stem cells heal knee Lady's own stem cells heal knee

Updated: Monday, January 20 2014 2:36 AM EST2014-01-20 07:36:02 GMT

Updated: Sunday, January 19 2014 5:00 PM EST2014-01-19 22:00:19 GMT

Updated: Sunday, January 19 2014 9:00 AM EST2014-01-19 14:00:13 GMT

Updated: Saturday, January 18 2014 11:00 AM EST2014-01-18 16:00:12 GMT

Updated: Saturday, January 18 2014 2:30 AM EST2014-01-18 07:30:46 GMT

CLEARWATER, FL (WFLA/NBC) - When Judy Loar, 68, could not bear to walk any longer due to excruciating pain in both of her knees from degenerative joint disease, she did what most people in her condition do, she went in for a surgical knee replacement.

After being released, Loar found out her knee cap had been set incorrectly.

Going through surgery again to fix her other knee was not an option, so Loar started researching other alternatives to ease the agony of bone-on-bone friction caused by her condition.

"I really did my research, because I knew I could go through another major surgery," said Loar, who became a patient of Dr. Dennis Lox.

See the article here:
Lady's own stem cells heal knee

Durham, NC (PRWEB) January 17, 2014

A new assessment tool is helping scientists determine which treatments might benefit patients with a type of eye disorder called limbal stem cell deficiency (LSCD). The tool, developed by researchers at University College London and Moorfields Eye Hospital in London and funded by the UKs National Institute for Health Research Biomedical Research Centre at these institutions, has already shown that the majority of these patients can benefit in the short term from a stem cell transplantation and up to 30 percent are still experiencing better sight three years later, according to the study published in the current issue of STEM CELLS Translational Medicine.

LSCD is an eye disorder in which the stem cells responsible for forming the surface skin of the cornea are destroyed by injury or disease. This results in pain, loss of vision and a cosmetically unpleasant appearance. Many new treatments, including limbal stem cell transplants, are emerging for this condition but their effectiveness remains to be proven.

Assessing how well they perform has been severely hampered by the lack of biomarkers for LSCD and/or validated tools for determining its severity, said Alex Shortt, M.D., Ph.D., of University College Londons Institute of Ophthalmology and lead investigator in the study. In virtually all studies of limbal stem cell transplantation to date the clinical outcome has been assessed subjectively by the investigating clinician. This is clearly open to significant measurement and reporting bias.

His teams aims, then, were to design and test the reliability of a new tool for grading LSCD, to define a set of core outcome measures to use in evaluating treatments and to demonstrate the treatments impact on two common types of LSCD: a genetic disorder called aniridia and Stevens-Johnson syndrome (SJS), an inflammatory disorder.

They began developing an assessment tool by paring down a list of clinical signs taken from previously published studies to four key LSCD indicators: corneal epithelial haze, superficial corneal neovascularization, corneal epithelial irregularity and corneal epithelial defect. A standardized grading plate was then produced for each of these parameters, ranging from normal to severe. They named their assessment method the Clinical Outcome Assessment in Surgical Trials of Limbal stem cell deficiency [COASTL] tool and validated its performance in 26 patients with varying degrees of LSCD.

Once they had the COASTL tool in place, they used it to evaluate treatment outcomes in 14 patients with aniridia or SJS. All had undergone a limbal epithelial transplantation (allo-CLET), using cells taken from a deceased donor, cultivated in the lab before being transplanted into the recipient.

The COASTL tool showed that following allo-CLET there was a decrease in LSCD severity and an increase in visual acuity up to 12 months post-treatment, but thereafter LSCD severity and visual acuity progressively deteriorated, Dr. Shortt said. However, despite a recurrence of clinical signs, the visual benefit persisted in 30 percent of aniridic and 25 percent of SJS patients at 36 months.

A reliable method of obtaining objective outcome data for surgical trials of limbal stem cell deficiency will greatly contribute to the effective evaluation of current and new treatments, said Anthony Atala, M.D., editor of STEM CELLS Translational Medicine and director of the Wake Forest Institute for Regenerative Medicine.

The full article, Three-Year Outcomes of Cultured Limbal Epithelial Allografts in Aniridia and Stevens-Johnson Syndrome Evaluated Using the Clinical Outcome Assessment in Surgical Trials Assessment Tool, can be accessed at http://www.stemcellstm.com.

Visit link:
New Assessment Tool Shows Potential of Stem Cells in Restoring LSCD Patients’ Sight

ROCHESTER, Minn., Jan. 17 (UPI) -- The U.S. Food and Drug Administration approved a clinical trial of heart failure patients to determine if using stem cells improves the heart, researchers say.

Dr. Andre Terzic, director of the Mayo Clinic's Center for Regenerative Medicine in Rochester, Minn., said the decade-long project using stem cells to repair -- "cure" -- damaged heart tissue could have implications for millions of Americans with heart disease.

The trial is scheduled to involve 240 heart failure patients from 40 hospitals in Europe and Israel.

The procedure could be a "paradigm shift" in the treatment of heart disease, Terzic told the (Minneapolis) Star Tribune.

The process, developed in collaborations with Cardio3 BioSciences of Belgium, involves harvesting stem cells from a patient's bone marrow in the hip, directing the cells to become "cardiopoietic" repair cells, then injecting them back into the heart to repair heart damage.

Dr. Atta Behfar, a researcher on Terzic's team, isolated hundreds of proteins involved in the transcription process that takes place when stem cells are converted to heart cells and identified eight proteins crucial to the process.

Early results are expected in 2015.

Read more:
Mayo Clinic to test adult stem cells to treat heart failure

Iran Among Three Top Countries In Extracting Stem Cells From Primary Teeth
.

By: DaNi Islam

Read this article:
Iran Among Three Top Countries In Extracting Stem Cells From Primary Teeth - Video

Stem Cells Revolutions: TRAILER
RENT or BUY film here: http://www.stemcellrevolutions.com Featuring beautiful hand-drawn animations and interviews with leading stem cell scientists, STEM CE...

By: Scottish Documentary Institute

The rest is here:
Stem Cells Revolutions: TRAILER - Video

Jan. 16, 2014 A research team has identified a protein that increases the transfer of mitochondria from mesenchymal stem cells to lung cells. In work published in The EMBO Journal, the researchers reveal that the delivery of mitochondria to human lung cells can rejuvenate damaged cells. The migration of mitochondria from stem cells to epithelial cells also helps to repair tissue damage and inflammation linked to asthma-like symptoms in mice.

"Our results show that the movement of mitochondria from stem cells to recipient cells is regulated by the protein Miro1 and is part of a well-directed process," remarked Anurag Agrawal, Professor at the CSIR-Institute of Genomics and Integrative Biology in Delhi, India, and one of the lead authors of the study. "The introduction of mitochondria into damaged cells has beneficial effects on the health of cells and, in the long term, we believe that mesenchymal stem cells could even be engineered to create more effective therapies for lung disease in humans."

Earlier work revealed that mitochondria can be transferred between cells through tunneling nanotubes, thread-like structures formed from the plasma membranes of cells that bridge between different types of cells. Stem cells can also use tunneling nanotubes to transfer mitochondria to neighboring cells and the number of these nanotubes increases under conditions of stress.

In the study, the protein Miro1 was shown to regulate the transfer of mitochondria from mesenchymal stem cells to epithelial cells. Stem cells that were engineered to have higher amounts of Miro1 were able to transfer mitochondria more efficiently and were therapeutically more effective when tested in mouse models of airway injury and asthma, compared to untreated cells.

"We hope to determine how this pathway might translate into better stem cell therapies for human disease," added Agrawal.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

The above story is based on materials provided by EMBO - excellence in life sciences.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Read the original post:
Stem cells overcome damage in other cells by exporting mitochondria